VERV

Insider Trades

Name	Value	Action	Price	Current Price
Lister TroyChief Scientific Officer $9.1k2.2k shares SellApr 2, 2025 $4.15 --
Dorval AllisonChief Financial Officer $14k3.4k shares SellApr 2, 2025 $4.15 --
Politi JasonChief Technical Ops. Off. $13k3.2k shares SellApr 2, 2025 $4.15 --
Ashe Andrew D.See Remarks $11k2.7k shares SellApr 2, 2025 $4.15 --
Nickerson JoanChief Administrative Officer $12k2.8k shares SellApr 2, 2025 $4.15 --
Kathiresan SekarDirector, Officer: Chief Executive Officer $41k9.8k shares SellApr 2, 2025 $4.15 --

News

247wallst.comThree Biotechs That Are Top Takeover Targets247wallst.comMay 18

Trade VERV

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc. is a biotechnology firm dedicated to pioneering gene-editing treatments for individuals afflicted with cardiovascular diseases. Their flagship experimental therapy, VERVE-101, represents a singular gene-editing intervention engineered to irreversibly inactivate the PCSK9 gene within the liver. The company is also progressing with an ANGPTL3 program, which similarly aims to permanently switch off the ANGPTL3 gene in the liver. To support its endeavors, Verve maintains several key partnerships, including a collaboration and licensing pact with Beam Therapeutics Inc., a development and option agreement with Acuitas Therapeutics, Inc., and a Cas9 gene-editing technology license from The Broad Institute and the President and Fellows of Harvard College. Incorporated in 2018 and headquartered in Cambridge, Massachusetts, the organization operated under the name Endcadia, Inc. until its rebranding to Verve Therapeutics, Inc. in January 2019.

CEO: Sekar Kathiresan
IPO Date: Jun 17, 2021

Market Data

Open: $11.13
High: $11.13
Low: $11.13
Volume: 10.3M
Avg Volume: 5.7M
52W High: $11.41
52W Low: $2.87

Valuation

Market Cap: $994M
Enterprise Value: $966M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-161M
Revenue: $32M
Net Income: $-199M
Cash: $173M
Debt: $70M

Events

EarningsAug 14

EPS est. -0.7 · actual -0.59